Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000131.xml
Synfacts 2021; 17(04): 0365
DOI: 10.1055/s-0040-1720320
DOI: 10.1055/s-0040-1720320
Synthesis of Natural Products and Potential Drugs
Synthesis of PF-07059013
Piotrowski DW.
*
et al.
Pfizer Worldwide Research & Development, Groton, USA
PF-07059013: A Noncovalent Modulator of Hemoglobin for Treatment of Sickle Cell Disease.
J. Med. Chem. 2021;
64: 326-342
DOI: 10.1021/acs.jmedchem.0c01518.
PF-07059013: A Noncovalent Modulator of Hemoglobin for Treatment of Sickle Cell Disease.
J. Med. Chem. 2021;
64: 326-342
DOI: 10.1021/acs.jmedchem.0c01518.
Key words
PF-07059013 - sickle cell anemia - biocatalysis - ketoreductase - Pfitzinger quinoline synthesis - Mitsunobu reaction
Significance
Sickle cell disease is a common genetic disorder that affects 15 million people worldwide. It is caused by a single point mutation on the β-chain of adult hemoglobin. PF-07059013 is a noncovalent modulator of hemoglobin that has entered phase I clinical trials for the treatment of sickle cell disease.
#
Comment
Key steps in the synthesis depicted are (1) the asymmetric reduction of ketone E using the ketoreductase KRED101 from Codexis to afford enantiopure F in 94% yield (>99% ee), (2) the construction of quinoline I using a Pfitzinger reaction, and (3) a Mitsunobu reaction that links fragments F and K.
#
#
Publication History
Article published online:
18 March 2021
© 2021. Thieme. All rights reserved
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany